HRP20030744A2 - The use of enantiomeric pure escitalopram - Google Patents

The use of enantiomeric pure escitalopram

Info

Publication number
HRP20030744A2
HRP20030744A2 HR20030744A HRP20030744A HRP20030744A2 HR P20030744 A2 HRP20030744 A2 HR P20030744A2 HR 20030744 A HR20030744 A HR 20030744A HR P20030744 A HRP20030744 A HR P20030744A HR P20030744 A2 HRP20030744 A2 HR P20030744A2
Authority
HR
Croatia
Prior art keywords
enantiomeric pure
pure escitalopram
escitalopram
enantiomeric
pure
Prior art date
Application number
HR20030744A
Other languages
English (en)
Inventor
Sanchez Connie
Jesper Lyng Jensen
Mørk Arne
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of HRP20030744A2 publication Critical patent/HRP20030744A2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
HR20030744A 2001-05-01 2003-09-16 The use of enantiomeric pure escitalopram HRP20030744A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200100684 2001-05-01
PCT/DK2002/000281 WO2002087566A1 (en) 2001-05-01 2002-05-01 The use of enantiomeric pure escitalopram

Publications (1)

Publication Number Publication Date
HRP20030744A2 true HRP20030744A2 (en) 2005-06-30

Family

ID=8160464

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20030744A HRP20030744A2 (en) 2001-05-01 2003-09-16 The use of enantiomeric pure escitalopram

Country Status (25)

Country Link
US (7) US20040198809A1 (xx)
EP (1) EP1385503A1 (xx)
JP (1) JP2004527551A (xx)
KR (2) KR20100012089A (xx)
CN (1) CN1509169A (xx)
AR (1) AR033308A1 (xx)
AT (1) AT10974U1 (xx)
BG (1) BG108379A (xx)
BR (1) BR0208283A (xx)
CA (1) CA2445843A1 (xx)
CZ (1) CZ20033267A3 (xx)
EA (1) EA200301195A1 (xx)
HR (1) HRP20030744A2 (xx)
HU (1) HUP0400054A3 (xx)
IL (1) IL158031A0 (xx)
IS (1) IS6954A (xx)
ME (1) MEP5908A (xx)
MX (1) MXPA03008777A (xx)
NO (1) NO20034538D0 (xx)
PL (1) PL367480A1 (xx)
SK (1) SK14612003A3 (xx)
UA (1) UA82828C2 (xx)
WO (1) WO2002087566A1 (xx)
YU (1) YU85303A (xx)
ZA (1) ZA200307102B (xx)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
IL158031A0 (en) * 2001-05-01 2004-03-28 Lundbeck & Co As H The use of enantiomeric pure escitalopram
NZ540281A (en) * 2002-12-23 2008-07-31 Lundbeck & Co As H Escitalopram hydrobromide and a method for the preparation thereof
US20050037983A1 (en) * 2003-03-11 2005-02-17 Timothy Dinan Compositions and methods for the treatment of depression and other affective disorders
AR047553A1 (es) * 2003-07-04 2006-01-25 Lundbeck & Co As H La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina
EP1691811B1 (en) * 2003-12-11 2014-07-23 Sunovion Pharmaceuticals Inc. Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
US20050196453A1 (en) 2004-03-05 2005-09-08 H. Lundbeck A/S Crystalline composition containing escitalopram
CA2558198A1 (en) * 2004-03-05 2005-09-15 H. Lundbeck A/S Crystalline composition containing escitalopram oxalate
TWI347942B (en) * 2005-06-22 2011-09-01 Lundbeck & Co As H Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
EA200801080A1 (ru) * 2005-10-14 2009-02-27 Х. Лундбекк А/С Стабильные фармацевтические лекарственные формы, содержащие эсциталопрам и бупропион
CA2625835A1 (en) 2005-10-14 2007-05-10 Forest Laboratories, Inc. Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion
US20070134322A1 (en) * 2005-12-14 2007-06-14 Forest Laboratories, Inc. Modified and pulsatile release pharmaceutical formulations of escitalopram
CN100353939C (zh) * 2006-01-05 2007-12-12 昆明积大制药有限公司 含西酞普兰和环糊精的抗抑郁口服药用组合物
US20070259952A1 (en) * 2006-05-02 2007-11-08 H. Lundbeck A/S Uses of escitalopram
TW200812993A (en) * 2006-05-02 2008-03-16 Lundbeck & Co As H New uses of escitalopram
US8252336B2 (en) * 2006-10-20 2012-08-28 Ratiopharm Gmbh Escitalopram and solid pharmaceutical composition comprising the same
US20100003313A1 (en) * 2006-10-27 2010-01-07 Hisamitsu Pharmaceutical Co.,Inc. Adhesive skin patch
EP2017271A1 (en) 2007-07-06 2009-01-21 Aurobindo Pharma Limited Process for the preparation of escitalopram
DK2185155T3 (en) * 2007-08-03 2018-01-02 Richter Gedeon Nyrt PHARMACEUTICAL COMPOSITIONS WITH DOPAMINE RECEPTOR LIGANDS AND TREATMENT METHODS USING DOPAMINE RECEPTOR LIGANDS
EP2248808B1 (en) * 2008-01-31 2014-07-16 Takeda Pharmaceutical Company Limited Prophylactic or therapeutic agent for attention deficit/hyperactivity disorder
ITMI20080768A1 (it) * 2008-04-24 2009-10-25 Abiogen Pharma Spa Procedimento per la preparazione di un composto in forma cristallina di 3-benzil-2-metil-2,3,3a,4,5,6,7,7a-ottaidro-benzo[d]isossazol-4-one
JP5740300B2 (ja) * 2009-02-27 2015-06-24 久光製薬株式会社 経皮投与製剤
US20180071269A1 (en) 2015-08-12 2018-03-15 Tianxin Wang Therapeutical methods, formulations and nutraceutical formulations
CA2982898C (en) * 2015-05-13 2023-08-29 A. Carlsson Research Ab Combination of dopamine stabilizing agent and an anti-depressive agent to treat a disorder characterized by debilitating fatigue

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1143702A (xx) * 1965-03-18
US4079135A (en) * 1973-12-13 1978-03-14 Imperial Chemical Industries Limited Morpholine derivatives as antidepressants
GB1526331A (en) * 1976-01-14 1978-09-27 Kefalas As Phthalanes
GB8419963D0 (en) * 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
GB8607313D0 (en) * 1986-03-25 1986-04-30 Ici Plc Pharmaceutical compositions
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
US4902710A (en) * 1988-12-14 1990-02-20 Eli Lilly And Company Serotonin and norepinephrine uptake inhibitors
US5114976A (en) * 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US4962128A (en) * 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
US5296507A (en) * 1990-09-06 1994-03-22 H.Lundbeck A/S Treatment of cerbrovascular disorders
US5708035A (en) * 1991-02-04 1998-01-13 Sepracor Inc. Methods of use and compositions of R(-) fluoxetine
EP0714663A3 (en) * 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
US5627196A (en) * 1995-01-17 1997-05-06 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5554383A (en) * 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
SE9501567D0 (sv) * 1995-04-27 1995-04-27 Astra Ab A new combination
US5846982A (en) * 1996-06-14 1998-12-08 Eli Lilly And Company Inhibition of serotonin reuptake
US5747494A (en) * 1996-06-28 1998-05-05 U C B S.A. Pharmaceutical compositions for the treatment of depressive disorders
US5958429A (en) * 1996-08-16 1999-09-28 Eli Lilly And Company Potentiation of serotonin response
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
US5776969A (en) * 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
US6069177A (en) * 1997-07-08 2000-05-30 The Hong Kong University Of Science And Technology 3-Hydroxy-propanamine derived neuronal reuptake inhibitors
SE9703375D0 (sv) * 1997-09-18 1997-09-18 Astra Ab A new combination
CZ292911B6 (cs) * 1997-11-11 2004-01-14 H. Lundbeck A/S Způsob výroby citalopramu
AU4850199A (en) * 1998-06-30 2000-01-17 Eli Lilly And Company Pyrrolidine and pyrroline derivatives having effects on serotonin related systems
US6150376A (en) * 1998-08-05 2000-11-21 Georgetown University Bi- and tri-cyclic aza compounds and their uses
PL199423B1 (pl) * 1998-10-20 2008-09-30 Lundbeck & Co As H Sposób wytwarzania citalopramu
ATE237604T1 (de) * 1999-04-14 2003-05-15 Lundbeck & Co As H Verfahren zur herstellung von citalopram
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
US6333357B1 (en) * 1999-11-05 2001-12-25 Be Able, Llc Behavior chemotherapy
UA77650C2 (en) * 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
CA2405025A1 (en) * 2000-04-24 2001-11-01 Aryx Therapeutics (2-aminoethyl) oxime derivatives for the treatment of depression
IL158031A0 (en) * 2001-05-01 2004-03-28 Lundbeck & Co As H The use of enantiomeric pure escitalopram

Also Published As

Publication number Publication date
IL158031A0 (en) 2004-03-28
HUP0400054A3 (en) 2007-03-28
EA200301195A1 (ru) 2004-04-29
US20040198809A1 (en) 2004-10-07
BR0208283A (pt) 2004-03-09
NO20034538L (no) 2003-10-09
US20040198810A1 (en) 2004-10-07
SK14612003A3 (sk) 2004-04-06
AR033308A1 (es) 2003-12-10
US20040198811A1 (en) 2004-10-07
YU85303A (sh) 2006-05-25
ZA200307102B (en) 2004-09-13
KR20040030609A (ko) 2004-04-09
JP2004527551A (ja) 2004-09-09
EP1385503A1 (en) 2004-02-04
BG108379A (bg) 2004-11-30
NO20034538D0 (no) 2003-10-09
US20080004338A1 (en) 2008-01-03
KR20100012089A (ko) 2010-02-05
CA2445843A1 (en) 2002-11-07
US20040192765A1 (en) 2004-09-30
MEP5908A (xx) 2010-02-10
CZ20033267A3 (en) 2004-06-16
US20040192766A1 (en) 2004-09-30
AT10974U1 (de) 2010-02-15
CN1509169A (zh) 2004-06-30
UA82828C2 (en) 2008-05-26
IS6954A (is) 2003-09-15
PL367480A1 (en) 2005-02-21
US20040192764A1 (en) 2004-09-30
MXPA03008777A (es) 2004-02-12
WO2002087566A1 (en) 2002-11-07
HUP0400054A2 (hu) 2004-04-28

Similar Documents

Publication Publication Date Title
HUP0400054A3 (en) The use of enantiomeric pure escitalopram
ZA200204020B (en) Use of anti-CTLA-4-antibodies.
GB0130645D0 (en) Cellectivity technology overview
EP1387687A4 (en) NEW USE
GB0125088D0 (en) New use
EP1453913A4 (en) SUBSTITUTED ALKANES COMPOUNDS AND USES THEREOF
GB0115181D0 (en) Novel use
GB0100762D0 (en) Novel use
HUP0500734A3 (en) Use of 2-alkoxyphenyl-substituted imidazotriazinones
GB0104554D0 (en) New uses
HK1066022A1 (en) Use of 1,1,1,3,3-pentafluorobutan
IL161178A0 (en) MODIFICATIONS OF SOLID 3-sn-PHOSPHOGLYCERIDES
GB0119920D0 (en) New use
HU0104370D0 (en) Honeyed schnaps of oerseg
GB0125482D0 (en) Uses of (s)-clenbuterol
TW511737U (en) New structure of micro-radiator
TW510531U (en) New structure of micro-radiator
TW510530U (en) New structure of micro-radiator
AU2002331285A1 (en) Use of 1,1,1,3,3-pentafluorobutan
GB0102601D0 (en) New Uses
GB0117913D0 (en) New use
GB0119693D0 (en) New Use
GB0119822D0 (en) New use
GB0119928D0 (en) New use
GB0115989D0 (en) New use

Legal Events

Date Code Title Description
ODRP Renewal fee for the maintenance of a patent

Payment date: 20050407

Year of fee payment: 4

A1OB Publication of a patent application
OBST Application withdrawn